KLP Kapitalforvaltning AS Trims Stock Holdings in Gilead Sciences, Inc. $GILD

KLP Kapitalforvaltning AS decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 790,808 shares of the biopharmaceutical company’s stock after selling 5,500 shares during the period. KLP Kapitalforvaltning AS’s holdings in Gilead Sciences were worth $97,064,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Personal CFO Solutions LLC raised its stake in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 76 shares during the last quarter. Moss Adams Wealth Advisors LLC raised its stake in Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares during the last quarter. SOA Wealth Advisors LLC. raised its stake in Gilead Sciences by 8.7% in the 4th quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 81 shares during the last quarter. Trivium Point Advisory LLC raised its stake in Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after acquiring an additional 83 shares during the last quarter. Finally, Greatmark Investment Partners Inc. raised its stake in Gilead Sciences by 0.3% in the 4th quarter. Greatmark Investment Partners Inc. now owns 29,200 shares of the biopharmaceutical company’s stock worth $3,584,000 after acquiring an additional 83 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $133.29 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $165.44 billion, a PE ratio of 19.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.39. The stock’s 50-day moving average price is $143.76 and its 200-day moving average price is $131.88.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the firm earned $1.90 EPS. The company’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 8.63 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were given a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is 48.45%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider directly owned 128,779 shares in the company, valued at approximately $18,152,687.84. The trade was a 2.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares in the company, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 294,280 shares of company stock worth $42,302,950. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on GILD shares. Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Argus raised their target price on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Scotiabank raised their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. UBS Group increased their price target on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $157.35.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks highlights Gilead as a long-term value pick, noting dividend yield, cash flow and valuation metrics that could make the stock attractive for buy-and-hold investors. This supports longer-term demand from value-focused funds. Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Lilly’s large (up to $7B) in‑vivo CAR‑T deal underscores industry momentum toward genetic/in‑vivo modalities — a structural trend that could increase competitive pressure in cell & gene spaces but also validates the big‑pharma market for such platforms. Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push
• Neutral Sentiment: Coverage notes and commentary (Seeking Alpha) show some investor caution ahead of quarterly results, which can increase intraday selling or volatility even if the author ultimately holds. This amplifies near‑term sentiment sensitivity around earnings. Gilead Sciences: Why I’m Tempted To Sell Ahead Of Q1 Earnings – But Won’t
• Neutral Sentiment: Recent market reports note Gilead’s share price has declined more than the broader market recently — a descriptive datapoint that can feed momentum selling but doesn’t by itself change fundamentals. Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
• Negative Sentiment: Zacks Research trimmed Q1–Q4 and FY2026 EPS estimates (small downgrades across quarters), lowering FY2026 from $8.34 to $8.29 in their model. Analyst cuts like these increase downside risk to guidance beats and can pressure the stock if investors reprice forward earnings.
• Negative Sentiment: Arcus halted a Gilead‑partnered late‑stage lung cancer trial — a direct negative for Gilead’s oncology partnership outcomes and future revenue potential from that program; trial halts often trigger re‑rating until clarity on cause and next steps. Arcus halts Gilead-partnered late-stage trial for lung cancer drug
• Negative Sentiment: Relative valuation/peer comparisons (coverage favoring Bristol Myers over Gilead) highlight BMY’s cheaper valuation and stronger near‑term growth narrative, which can shift investor allocation away from GILD in the large‑cap biotech cohort. Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.